Disclosure Statements

Forward Looking Statements
Some of the information presented here today may contain projections or other forward-looking statements regarding future events or the future financial performance of the Company. These statements are based on management’s current expectations and the actual events or results may differ materially and adversely from these expectations. We refer you to the documents the Company files from time to time with the Securities and Exchange Commission, specifically, the Company’s annual reports on Form 10-K, its quarterly reports on Form 10-Q, and its current reports on Form 8-K. These documents identify important risk factors that could cause the actual results to differ materially from those contained in the Company’s projections or forward-looking statements.

Non-GAAP Financial Measures
In this presentation, the Company’s financial results and financial guidance are provided in accordance with accounting principles generally accepted in the United States (GAAP) and using certain non-GAAP financial measures. The Company’s financial measures under GAAP include substantial one-time charges related to its acquisitions and ongoing amortization expense related to acquired intangible assets that will be recognized over the useful lives of the assets. Management believes that presentation of operating results that excludes these items provides useful supplemental information to investors and facilitates the analysis of the Company’s core operating results and comparison of operating results across reporting periods. Management also uses non-GAAP financial measures to establish budgets and to manage the Company’s business. A reconciliation of the GAAP to non-GAAP financial guidance is provided below.

<table>
<thead>
<tr>
<th></th>
<th>Fiscal Year 2015</th>
</tr>
</thead>
<tbody>
<tr>
<td>GAAP diluted net income per share</td>
<td>$1.75 - $1.85</td>
</tr>
<tr>
<td>Acquisition – amortization of intangible assets</td>
<td>$0.15</td>
</tr>
<tr>
<td>Non-GAAP diluted net income per share</td>
<td>$1.90 - $2.00</td>
</tr>
</tbody>
</table>
Myriad Genetics is dedicated to saving lives and improving the quality of life of patients through the discovery and commercialization of novel, transformative diagnostic tests across major diseases:

- Largest molecular diagnostic clinical laboratory in the world
- Global leader in hereditary cancer risk assessment
- Pioneer in personalized medicine and companion diagnostics
- Trailblazer in autoimmune disease management
- $778 million in FY2014 revenues (27% growth over FY2013)
The Myriad Vision

A TRUSTED ADVISOR ANSWERING PATIENT’S MOST PRESSING CONCERNS

With what?

myChoice
Rx Selection

myRisk
Risk Assessment

Should I?

myPlan
Prognosis

myPath
Diagnosis

Will I?

Do I?

Oncology
Preventive Care
Urology
Autoimmune
Dermatology
Neuroscience
Multiple Growth Opportunities

Business Strategy

- Transition Hereditary Cancer Market
- Diversify the Portfolio
- Expand Global Presence

Fuel Strong Long-Term Top Line Growth
Value of Identifying High Risk Patients

- Identifying hereditary disease saves lives
- Patients can take preventive measures to reduce risk of cancer
- Preventing cancer saves healthcare system money
myRisk Hereditary Cancer™

- 25 gene panel assesses cancer risk
- Over 50 million covered lives
- All genes are clinically actionable
- Identifies risks for eight cancers
- Finds 51% more people at risk for breast cancer than BRCA
- Building database on all 25 genes
- Test accuracy is 99.99%
- $5 billion global market
Multiple Growth Opportunities

Business Strategy

Transition Hereditary Cancer Market

Diversify the Portfolio

Expand Global Presence

Fuel Strong Long-Term Top Line Growth
# 4 in 6 Pipeline Projects

<table>
<thead>
<tr>
<th></th>
<th>Risk?</th>
<th>Diagnosis?</th>
<th>Prognosis?</th>
<th>Therapy?</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Oncology</strong></td>
<td>☑ 4</td>
<td>1</td>
<td>☑ 1</td>
<td>6</td>
</tr>
<tr>
<td><strong>Preventive Care</strong></td>
<td>☑</td>
<td>1</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Urology</strong></td>
<td>1</td>
<td>1</td>
<td>☑</td>
<td>1</td>
</tr>
<tr>
<td><strong>Dermatology</strong></td>
<td>☑ 1</td>
<td>☑</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td><strong>Neuroscience</strong></td>
<td>2</td>
<td></td>
<td></td>
<td>1</td>
</tr>
<tr>
<td><strong>Autoimmune</strong></td>
<td>1</td>
<td></td>
<td></td>
<td>☑ 2</td>
</tr>
</tbody>
</table>

☑️ Currently Marketed  ☻ Under Development
## Product Pipeline

### Significant Revenue Growth Drivers

<table>
<thead>
<tr>
<th>Near Term 1 year</th>
<th>Mid Term 2-3 years</th>
<th>Long Term 3 years +</th>
</tr>
</thead>
<tbody>
<tr>
<td>▪ myRisk HC</td>
<td>▪ myPath Melanoma</td>
<td>▪ myChoice HRD (PARP)</td>
</tr>
<tr>
<td>▪ Prolaris</td>
<td>▪ myPlan Lung Cancer</td>
<td>▪ myPath BiPolar</td>
</tr>
<tr>
<td>▪ Vectra DA</td>
<td>▪ myChoice HRD</td>
<td>▪ myRisk Schizophrenia</td>
</tr>
<tr>
<td>▪ EndoPredict</td>
<td>▪ myPlan Renal Cancer</td>
<td>▪ Juvenile RA</td>
</tr>
<tr>
<td>▪ BRACAnalysis CDx</td>
<td></td>
<td>▪Psoriatic Arthritis</td>
</tr>
<tr>
<td>▪ Tumor BRACAnalysis CDx</td>
<td></td>
<td>▪ Ankylosing Spondylitis</td>
</tr>
</tbody>
</table>
Global Market Size = $18 Billion

- myRisk HC: $6.0
- myChoice HRD/BRACAnalysis CDx: $5.0
- Prolaris: $3.0
- EndoPredict/myPlan Lung Cancer: $2.0
- myPath Melanoma: $1.0
- Vectra DA: $1.0
▪ 46 gene panel assesses aggressiveness of prostate cancer
▪ Most prostate cancer patients don’t require surgery
▪ 85% to 90% have treatment with side effects
▪ Validated in seven peer reviewed publications with gold standard outcomes of survival and metastases
▪ ProLaris changed treatment decisions for up to 65% of patients
▪ $2 billion global market
▪ Recently received draft LCD from Medicare covering the test for low risk patients

* Data presented at ASCO 2014
myPath Melanoma™

- 23 gene panel for diagnosis of melanoma
- Misdiagnosis is leading cause of malpractice suits
- Accurately differentiates between melanoma and benign skin lesions
- Effective for all four major melanoma subtypes
- myPath changed treatment decisions for 35% of patients
- 14% of biopsies in U.S. are indeterminate every year
- $1 billion global market

myPath Accurately Identifies Melanoma Skin Cancer

- 90% Sensitivity
- 91% Specificity

* Data presented at ASCO 2014
• 12 protein panel measures disease activity in RA patients
• 1.5 million adults with rheumatoid arthritis in U.S
• Predicts irreversible joint damage in RA patients
• Guides treatment decisions
• 2-6 tests needed each year for rest of patient’s life
• myRA patient app facilitates patient monitoring
• $3.0 billion global market
• 8 gene panel guides chemotherapy for breast cancer patients
• 60% of patients treated will not benefit from chemotherapy
• Test performed on site in cancer center
• No confusing intermediate results
• 13 clinical studies published with over 2,200 patients
• 250,000 breast cancer candidates in Europe each year
• $375 million European Market

* Data Published in Annals of Oncology 2012
myPlan Lung Cancer™

- 31 gene panel guides lung cancer chemotherapy
- Accurately predicts risk of dying from lung cancer
- Benefits patients with Stage 1 or Stage 2 lung cancer
- Stronger predictor than tumor size or stage of disease
- 34,000 early stage lung cancer patients in the U.S. every year
- $250 million global market

myPlan Predicts Lung Cancer Survival

*Validation of a Proliferation-based Expression Signature as Prognostic Marker in Early Stage Lung Adenocarcinoma (Bueno)*
Identify cancer patients with tumors that lack the ability to repair DNA
Likely to respond to DNA damaging agents (PARP or platinum drugs)
2,000,000 patients per year (U.S. & Europe) potentially eligible

Ovarian Cancer Patients Testing Positive

- Journal of Clinical Oncology August 2010; British Journal of Cancer November, 2012
### CDx Development Projects Underway

<table>
<thead>
<tr>
<th>PARP Inhibitors</th>
<th>BRACAnalysisCDx</th>
<th>Tumor BRACAnalysisCDx</th>
<th>myChoice</th>
</tr>
</thead>
<tbody>
<tr>
<td>Current indications in Phase 3 clinical trials: TNBC, Neoadjuvant TNBC, Metastatic TNBC, adjuvant TNBC, neoadjuvant ovarian, MetBC Her 2-/ER+</td>
<td>• Signed research collaboration with ABBV and TSRO • Expect to announce Phase 3 clinical trials</td>
<td>• Signed research collaborations with TSRO and BMRN • Expect to announce Phase 3 clinical trials</td>
<td></td>
</tr>
<tr>
<td>Current partners: ABBV, AZN, BMRN, Janssen (JNJ), TSRO, and other undisclosed partners</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Platinum Therapies</td>
<td>• TNBC Neoadjuvant</td>
<td>NA</td>
<td>• TNBC Neo &amp; Met BC</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Test predicts patient response to PARP inhibitors

PDUFA date for olaparib is scheduled for January 3, 2015.

All four PMA modules submitted; FDA facility inspection complete.

In nine Phase 3 clinical studies

Studying PARP inhibitor benefit in ovarian, breast, lung, prostate, gastric, and pancreatic cancers

BRCA Positive Patients Benefit from Olaparib

* Data presented at ASCO, 2013
Test predicts patient response to PARP inhibitors

EMA CHMP label recommendation supports tumor testing; test launched in Europe

Tumor testing finds up to 50% more responders than conventional germ line testing.

Recently announced collaborations with Tesaro and AbbVie on Tumor BRACAnalysis CDx

Finds Up to 50% More Patients Who Will Respond

% of Ovarian Cancer Patients With a Deleterious Mutation

- Germ Line Testing: 15.0%
- Tumor BRACAnalysis CDx: 22.0%

* Data presented at the European Society of Medical Oncology Meeting 2014
Test uses three technologies to predict patient response to:
- Platinum Drugs
- PARP inhibitor Drugs

Current cancers being studied in clinical trials represent a 900,000 patient U.S. opportunity annually.

Only 30% of patients benefit from platinum drugs; high HRD patients have a 70% response rate.

Launch scheduled for 2H FY2015.

$6 billion global market.

* Data presented at SABCS, 2012
Multiple Growth Opportunities

Business Strategy

Transition Hereditary Cancer Market

Diversify the Portfolio

Expand Global Presence

Fuel Strong Long-Term Top Line Growth
- 45 person European sales team
- Distributors in 80 countries
- Revenue up 109% in FY 2014
- Strong revenue growth from myRisk, Endopredict, BRACAnalysis, and Prolaris
- Launch of Vectra DA in 1H FY15
- Major opportunity with PARP inhibitors in European market
- $8 billion European market
Delivering Strong Growth

Revenue

- FY11: $402
- FY12: $496
- FY13: $613
- FY14: $778

Adjusted EPS

- FY11: $1.11
- FY12: $1.30
- FY13: $1.77
- FY14: $2.43

25% CAGR

30% CAGR
### Fiscal Year 2015 Guidance

#### Revenue Guidance (Millions of Dollars)

- **Total Revenue**: 800 - 820

#### Earnings Guidance (Dollars)

- **Adjusted Diluted EPS**: 1.90 - 2.00
Myriad Core Competencies

- **Pioneer in Molecular Diagnostics:**
  - 13 proprietary molecular diagnostic products on market
  - Commercial products in oncology, urology, rheumatology, dermatology, and women’s healthcare
  - Expert in all three biomarker technologies (DNA, RNA, and protein)
  - Industry leading pipeline of 10 molecular diagnostic products

- **Trailblazer in Personalized Medicine:**
  - First test to assess prostate cancer survival
  - First test to assess rheumatoid arthritis disease activity
  - First FDA approved complex companion diagnostic
  - First companion diagnostic test to assess HRD